Fibrate therapy and circulating adiponectin concentrations: Asystematic review and meta-analysis of randomized placebo-controlled trials

A.H. Sahebkar, Gerald Watts

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Several lines of evidence have indicated the insulin-sensitizing, anti-diabetic and anti-atherosclerotic properties of adiponectin, as well as the inverse association between circulating levels of this adipokine and development of cardiovascular outcomes. Improvement of adiponectin status has been reported as a pleiotropic effect of fibrate therapy, but the findings have not been conclusive. Objective: To systematically review and meta-analyze available evidence from randomized placebo-controlled trials (RCTs) on the impact of fibrate therapy on circulating levels of adiponectin. Methods: A comprehensive literature search in Medline was carried out to identify RCTs comparing the effect of fibrate therapy vs. placebo on circulating concentrations of adiponectin. A meta-analysis of eligible studies was performed using a random-effects model. Quality assessment, sensitivity analysis and publication bias evaluations were conducted using standard methods. Results: Twelve RCTs comprising 443 cases and 437 controls met the selection criteria for systematic review, out of which 9 RCTs (399 cases and 401 controls) were included in the meta-analysis. Quantitative data synthesis revealed a significant effect for fibrate therapy in increasing circulating adiponectin levels (weighed mean difference: 0.38μg/mL; 95% confidence interval: 0.13-0.63μg/mL; p=0.003). The effect size remained statistically significant when restricting the analysis to fenofibrate trials [0.31 (0.21-0.42) μg/mL; p
Original languageEnglish
Pages (from-to)110-120
JournalAtherosclerosis
Volume230
Issue number1
DOIs
Publication statusPublished - 2013

    Fingerprint

Cite this